Evaluating the value of dynamic procalcitonin and presepsin measurements for patients with severe sepsis

Bosurgi, 2015, Sepsis: a need for new solutions, Lancet Infect Dis, 15, 498, 10.1016/S1473-3099(15)70030-7 Dellinger, 2013, Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012, Crit Care Med, 41, 580, 10.1097/CCM.0b013e31827e83af Wacker, 2013, Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis, Lancet Infect Dis, 13, 426, 10.1016/S1473-3099(12)70323-7 Jensen, 2006, Procalcitonin increase in early identification of critically ill patients at high risk of mortality, Crit Care Med, 34, 2596, 10.1097/01.CCM.0000239116.01855.61 Bouadma, 2010, Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentrer and ranomised controlled trial, Lancet, 375, 463, 10.1016/S0140-6736(09)61879-1 de Azevedo, 2015, Prognostic evaluation of severe sepsis and septic shock: procalcitonin clearance vs Δ sequential organ failure assessment, J Crit Care, 30, 219, 10.1016/j.jcrc.2014.08.018 Schuetz, 2013, Procalcitonin decrease over 72hours in US critical care units predicts fatal outcome in sepsis patients, Crit Care, 17, R115, 10.1186/cc12787 Pieralli, 2015, Procalcitoninkinetics in the first 72hours predicts 30-day mortality in severely ill septic patients admitted to an intermediate care unit, J Clin Med Res, 7, 706, 10.14740/jocmr2251w Masson, 2014, Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the albumin Italian outcome sepsis trial, Crit Care, 18, R6, 10.1186/cc13183 Jung, 2013, Procalcitonin biomarker kinetics fails to predict treatment response in perioperative abdominal infection with septic shock, Crit Care, 17, R255, 10.1186/cc13082 Davies, 2015, Procalcitonin, J Clin Pathol, 68, 675, 10.1136/jclinpath-2014-202807 Medzhitov, 2000, Innate immunity, N Engl J Med, 343, 338, 10.1056/NEJM200008033430506 Chenevier-Gobeaux, 2015, Presepsin (sCD14-ST), an innate immune response marker in sepsis, Clin Chim Acta, 450, 97, 10.1016/j.cca.2015.06.026 Endo, 2014, Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study, J Infect Chemother, 20, 30, 10.1016/j.jiac.2013.07.005 Kweon, 2014, Usefulness of presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population, J Crit Care, 29, 965, 10.1016/j.jcrc.2014.06.014 Zheng, 2015, The accuracy of presepsin for the diagnosis of sepsis from SIRS: a systematic review and meta-analysis, Ann Intensive Care, 5, 48, 10.1186/s13613-015-0089-1 Behnes, 2014, Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment, Crit Care, 18, 507, 10.1186/s13054-014-0507-z Liu, 2013, Diagnostic value and prognostic evaluation of presepsin for sepsis in an emergency department, Crit Care, 17, R244, 10.1186/cc13070 Masson, 2015, Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial, Intensive Care Med, 41, 12, 10.1007/s00134-014-3514-2 Calandra, 2005, International sepsis forum definition of infection in the ICU consensus conference. The international sepsis forum consensus conference on definitions of infection in the intensive care unit, Crit Care Med, 33, 1538, 10.1097/01.CCM.0000168253.91200.83 Vincent, 1996, The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine, Intensive Care Med, 22, 707, 10.1007/BF01709751 Knaus, 1985, APACHE II: a severity of disease classification system, Crit Care Med, 13, 818, 10.1097/00003246-198510000-00009 Rhodes, 2015, The surviving sepsis campaign bundles and outcome: results from the international multicentre prevalence study on sepsis (the IMPreSS study), Intensive Care Med, 41, 1620, 10.1007/s00134-015-3906-y Fleischmann, 2016, Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations, Am J Respir Crit Care Med, 193, 259, 10.1164/rccm.201504-0781OC Guan, 2011, Dynamic change of procalcitonin, rather than concentration itself, is predictive of survival in septic shock patients when beyond 10ng/mL, Shock, 36, 570, 10.1097/SHK.0b013e31823533f9 Wright, 1990, CD14, a receptor for complex of lipopolysaccharide (LPS) and LPS binding protein, Science, 249, 1431, 10.1126/science.1698311 Gibot, 2005, Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis, Crit Care Med, 33, 792, 10.1097/01.CCM.0000159089.16462.4A